In vitro evaluation and mitigation of niclosamide’s liabilities as a covid-19 treatment

HIGHLIGHTS

• who: Jesse W. Wotring et al. from the Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA have published the research: In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment, in the Journal: Vaccines 2022, 10, 1284. of /2022/
• what: The authors used high-content imaging-based immunofluorescence assays in two different cell models to assess these limitations and evaluate the potential for using niclosamide as a COVID-19 antiviral. The authors show that despite promising preliminary reports the antiviral efficacy of niclosamide overlaps with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.